Skip to main content

Rezivertinib Generates Promising CNS Efficacy in NSCLC With an EGFR T790M Mutation

*June 2023*

Rezivertinib (BPI-7711) showed promising clinical central nervous system (CNS) efficacy among patients with advanced non–small cell lung cancer (NSCLC) with EGFR T790M mutation and CNS metastases.​​

The study included individual data from 2 different single-arm, phase 1 (NCT03386955) and phase 2b studies (NCT03812809) to assess the CNS response of rezivertinib in advanced NSCLC patients with an EGFR T790M mutation who had progressed following prior treatment including first- or second-generation EGFR TKIs.

Findings showed that in the CNS full analysis set (cFAS), the CNS objective response rate (CNS-ORR) was 32.0% (95% CI, 24.6%-40.1%) and the CNS disease control rate (CNS-DCR) was 42.0% (95% CI, 34.0%-50.3%), while in the CNS evaluable for response set(cEFR), these rates were 68.9% (95% CI, 53.4%-81.8%) and 100% (95% CI, 92.1%-100.0%). Read more.